Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Epidemiology

Background:

• Statins are generally well-tolerated cholesterol-lowering drugs, but rare adverse events (AEs) can occur.
• Rosuvastatin is a recently approved statin requiring ongoing safety assessment.
• Existing data from clinical trials and spontaneous reports suggest rosuvastatin's safety profile aligns with comparator statins.

Purpose of the Study:

• To present the rationale and methodology of a comprehensive pharmacoepidemiology program for rosuvastatin.
• To complement existing safety data with real-world evidence from a large patient cohort.
• To continuously assess the benefit-risk profile of rosuvastatin.

Main Methods:

• A multi-component pharmacoepidemiology program involving nine studies and over 50,000 patients treated with rosuvastatin.
• Patient characteristics studies: analyzing drug utilization patterns of new rosuvastatin users versus other statins in automated databases.
• Safety evaluation studies: examining specific AE rates and risk factors in statin users using prospective data and medical record review.
• Independent Prescription-Event Monitoring (PEM) study: monitoring significant events reported by general practitioners.

Main Results:

• The program is designed to provide a progressive and comprehensive assessment of rosuvastatin's safety.
• It aims to validate findings from clinical trials and spontaneous reporting systems.
• The methodology allows for detailed analysis of patient characteristics, drug utilization, and specific adverse events.

Conclusions:

• The rosuvastatin pharmacoepidemiology program is a robust initiative to ensure ongoing safety monitoring.
• It will provide valuable real-world data to complement clinical trial findings.
• The program is essential for a thorough understanding of rosuvastatin's benefit-risk profile.